PDT Partners LLC Buys Shares of 18,129 RxSight, Inc. (NASDAQ:RXST)

PDT Partners LLC purchased a new position in shares of RxSight, Inc. (NASDAQ:RXST) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 18,129 shares of the company’s stock, valued at approximately $896,000.

Several other large investors also recently added to or reduced their stakes in RXST. Amalgamated Bank boosted its position in RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after purchasing an additional 207 shares during the period. Principal Financial Group Inc. grew its stake in RxSight by 0.7% in the 3rd quarter. Principal Financial Group Inc. now owns 36,046 shares of the company’s stock valued at $1,782,000 after buying an additional 240 shares in the last quarter. Crossmark Global Holdings Inc. grew its stake in RxSight by 3.2% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock valued at $473,000 after buying an additional 242 shares in the last quarter. RiverPark Advisors LLC raised its holdings in RxSight by 9.6% during the 2nd quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock valued at $203,000 after acquiring an additional 297 shares during the period. Finally, CWM LLC lifted its position in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

RxSight Price Performance

RXST stock opened at $46.88 on Monday. The firm has a 50 day simple moving average of $48.58 and a two-hundred day simple moving average of $52.26. The stock has a market cap of $1.89 billion, a PE ratio of -56.48 and a beta of 1.19. RxSight, Inc. has a one year low of $28.88 and a one year high of $66.54.

Insider Transactions at RxSight

In other RxSight news, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the transaction, the director now directly owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jesse Anderson Corley acquired 11,111 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was acquired at an average cost of $45.37 per share, with a total value of $504,106.07. Following the purchase, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. This represents a 2.43 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 62,702 shares of company stock valued at $3,059,197. Insiders own 9.36% of the company’s stock.

Wall Street Analysts Forecast Growth

RXST has been the topic of a number of analyst reports. Jefferies Financial Group started coverage on RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective on the stock. Oppenheimer lowered their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Wells Fargo & Company decreased their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, Stifel Nicolaus cut their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight presently has a consensus rating of “Buy” and a consensus target price of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.